STANDARD BIOTOOLS INC
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| STANDARD BIOTOOLS INC. | ||
| Dated: March 10, 2025 | By: | /s/ Michael Egholm, Ph.D. |
|---|---|---|
| Michael Egholm, Ph.D. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Egholm, Ph.D., and Alex Kim, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Form 10-K, and any amendments thereof, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/Michael Egholm, Ph.D. | President and Chief Executive Officer (Principal Executive Officer); Director | March 10, 2025 |
| Michael Egholm, Ph.D. | ||
| /s/Alex Kim | Chief Financial Officer (Principal Financial and Accounting Officer) | March 10, 2025 |
| Alex Kim | ||
| /s/ Tom Carey | Chairman of the Board of Directors | March 10, 2025 |
| Tom Carey | ||
| /s/ Fenel M. Eloi | Director | March 10, 2025 |
| Fenel M. Eloi | ||
| /s/ Eli Casdin | Director | March 10, 2025 |
| Eli Casdin | ||
| /s/ Kathy Hibbs | Director | March 10, 2025 |
| Kathy Hibbs | ||
| /s/ Troy Cox | Director | March 10, 2025 |
| Troy Cox | ||
| /s/ Frank Witney, Ph.D. | Director | March 10, 2025 |
| Frank Witney, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.